• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Risk factors for infection or colonization with CTX-M extended-spectrum-β-lactamase-positive Escherichia coli.产 CTX-M 型超广谱β-内酰胺酶阳性大肠埃希菌感染或定植的危险因素。
Antimicrob Agents Chemother. 2012 Nov;56(11):5575-80. doi: 10.1128/AAC.01136-12. Epub 2012 Aug 13.
2
Bacteremia due to extended-spectrum beta -lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge.CTX-M 时代产超广谱β-内酰胺酶大肠埃希菌所致菌血症:一项新的临床挑战。
Clin Infect Dis. 2006 Dec 1;43(11):1407-14. doi: 10.1086/508877. Epub 2006 Oct 25.
3
Detection of Escherichia coli and associated β-lactamases genes from diabetic foot ulcers by multiplex PCR and molecular modeling and docking of SHV-1, TEM-1, and OXA-1 β-lactamases with clindamycin and piperacillin-tazobactam.通过多重 PCR 检测糖尿病足溃疡中的大肠杆菌及其相关β-内酰胺酶基因,并对 SHV-1、TEM-1 和 OXA-1 β-内酰胺酶与克林霉素和哌拉西林-他唑巴坦进行分子建模和对接。
PLoS One. 2013 Jul 4;8(7):e68234. doi: 10.1371/journal.pone.0068234. Print 2013.
4
Antimicrobial susceptibility of well-characterised multiresistant CTX-M-producing Escherichia coli: failure of automated systems to detect resistance to piperacillin/tazobactam.特征明确的产超广谱β-内酰胺酶(CTX-M)多重耐药大肠埃希菌的抗菌药敏性:自动化系统检测哌拉西林/他唑巴坦耐药性的失败
Int J Antimicrob Agents. 2008 Oct;32(4):333-8. doi: 10.1016/j.ijantimicag.2008.04.023. Epub 2008 Aug 12.
5
Comparison of the risk of acquiring in vitro resistance to doripenem and tazobactam/piperacillin by CTX-M-15-producing Escherichia coli.产CTX-M-15的大肠埃希菌对多利培南及他唑巴坦/哌拉西林产生体外耐药性风险的比较
J Infect Chemother. 2015 May;21(5):381-4. doi: 10.1016/j.jiac.2015.01.006. Epub 2015 Jan 23.
6
Characterization of Piperacillin/Tazobactam-Resistant Klebsiella oxytoca Recovered from a Nosocomial Outbreak.从医院感染暴发中分离出的耐哌拉西林/他唑巴坦产酸克雷伯菌的特征分析
PLoS One. 2015 Nov 5;10(11):e0142366. doi: 10.1371/journal.pone.0142366. eCollection 2015.
7
In the literature. Piperacillin-tazobactam and extended-spectrum β-lactamase--producing Escherichia coli.在文献中。哌拉西林-他唑巴坦与产超广谱β-内酰胺酶的大肠埃希菌。
Clin Infect Dis. 2013 Nov;57(10):iii-iv.
8
Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli.哌拉西林-他唑巴坦、头孢吡肟和厄他培南治疗产超广谱β-内酰胺酶大肠埃希菌所致尿路感染的随机对照试验
BMC Infect Dis. 2017 Jun 7;17(1):404. doi: 10.1186/s12879-017-2502-x.
9
Inoculum effect on the efficacies of amoxicillin-clavulanate, piperacillin-tazobactam, and imipenem against extended-spectrum β-lactamase (ESBL)-producing and non-ESBL-producing Escherichia coli in an experimental murine sepsis model.在实验性脓毒症小鼠模型中,接种物对产超广谱β-内酰胺酶(ESBL)和非产 ESBL 大肠埃希菌的阿莫西林克拉维酸、哌拉西林他唑巴坦和亚胺培南疗效的影响。
Antimicrob Agents Chemother. 2013 May;57(5):2109-13. doi: 10.1128/AAC.02190-12. Epub 2013 Feb 25.
10
[Replacement of third-generation cephalosporins by piperacillin-tazobactam decreases colonization of extended-spectrum beta-lactamases-producing intestinal Escherichia coli].用哌拉西林-他唑巴坦替代第三代头孢菌素可减少产超广谱β-内酰胺酶的肠道大肠杆菌的定植
Zhonghua Nei Ke Za Zhi. 2007 Sep;46(9):714-7.

引用本文的文献

1
Comparison of the efficacy of carbapenems and cephalosporins for postoperative treatment of perforated appendicitis in children.碳青霉烯类与头孢菌素类用于儿童穿孔性阑尾炎术后治疗的疗效比较
World J Gastrointest Surg. 2025 Apr 27;17(4):104712. doi: 10.4240/wjgs.v17.i4.104712.
2
The Challenges of The Diagnostic and Therapeutic Approach of Patients with Infectious Pathology in Emergency Medicine.急诊医学中感染性疾病患者诊断与治疗方法面临的挑战
J Pers Med. 2023 Dec 29;14(1):46. doi: 10.3390/jpm14010046.
3
Risk Factors for Community Colonization With Extended-Spectrum Cephalosporin-Resistant Enterobacterales (ESCrE) in Botswana: An Antibiotic Resistance in Communities and Hospitals (ARCH) Study.博茨瓦纳社区中产超广谱头孢菌素耐药肠杆菌科细菌(ESCrE)定植的危险因素:社区和医院抗生素耐药性研究(ARCH)。
Clin Infect Dis. 2023 Jul 5;77(Suppl 1):S89-S96. doi: 10.1093/cid/ciad259.
4
Comparative Effectiveness of Ceftriaxone plus Metronidazole versus Anti-Pseudomonal Antibiotics for Perforated Appendicitis in Children.头孢曲松联合甲硝唑对比抗假单胞菌抗生素治疗儿童穿孔性阑尾炎的疗效比较。
Surg Infect (Larchmt). 2019 Jul;20(5):399-405. doi: 10.1089/sur.2018.234. Epub 2019 Mar 15.
5
Meta-analysis of proportion estimates of Extended-Spectrum-Beta-Lactamase-producing Enterobacteriaceae in East Africa hospitals.东非医院产超广谱β-内酰胺酶肠杆菌科细菌比例估计的Meta分析。
Antimicrob Resist Infect Control. 2016 May 14;5:18. doi: 10.1186/s13756-016-0117-4. eCollection 2016.
6
Clinical management of infections caused by multidrug-resistant Enterobacteriaceae.多重耐药肠杆菌科细菌所致感染的临床管理
Ther Adv Infect Dis. 2013 Apr;1(2):49-69. doi: 10.1177/2049936113476284.
7
Intestinal decontamination of multidrug-resistant Klebsiella pneumoniae after recurrent infections in an immunocompromised host.免疫功能低下宿主反复感染后对多重耐药肺炎克雷伯菌进行肠道去污处理。
Diagn Microbiol Infect Dis. 2014 Sep;80(1):87-9. doi: 10.1016/j.diagmicrobio.2014.06.006. Epub 2014 Jun 21.
8
Risk factors associated with the community-acquired colonization of extended-spectrum beta-lactamase (ESBL) positive Escherichia Coli. an exploratory case-control study.与社区获得性产超广谱β-内酰胺酶(ESBL)阳性大肠杆菌定植相关的危险因素。一项探索性病例对照研究。
PLoS One. 2013 Sep 11;8(9):e74323. doi: 10.1371/journal.pone.0074323. eCollection 2013.
9
A call to action for antimicrobial stewardship in the emergency department: approaches and strategies.呼吁在急诊科采取抗菌药物管理措施:方法和策略。
Ann Emerg Med. 2013 Jul;62(1):69-77.e2. doi: 10.1016/j.annemergmed.2012.09.002. Epub 2012 Nov 2.

本文引用的文献

1
Risk factors and outcomes of Escherichia coli bacteremia caused by strains that produce CTX-M or non-CTX-M extended-spectrum-beta-lactamases.产 CTX-M 或非 CTX-M 型超广谱β-内酰胺酶的大肠埃希菌菌血症的危险因素和结局。
Eur J Clin Microbiol Infect Dis. 2011 Jan;30(1):33-9. doi: 10.1007/s10096-010-1048-2. Epub 2010 Sep 17.
2
Cephalosporin and fluoroquinolone combinations are highly associated with CTX-M β-lactamase-producing Escherichia coli: a case-control study in a French teaching hospital.头孢菌素和氟喹诺酮类药物联合使用与产 CTX-M 型β-内酰胺酶大肠埃希菌高度相关:法国教学医院的一项病例对照研究。
Clin Microbiol Infect. 2011 Nov;17(11):1746-51. doi: 10.1111/j.1469-0691.2010.03349.x. Epub 2011 Apr 12.
3
Risk factors for fluconazole resistance in patients with Candida glabrata bloodstream infection: potential impact of control group selection on characterizing the association between previous fluconazole use and fluconazole resistance.光滑念珠菌血流感染患者中氟康唑耐药的危险因素:对照组选择对描述氟康唑使用与氟康唑耐药之间关联的潜在影响。
Am J Infect Control. 2010 Aug;38(6):456-60. doi: 10.1016/j.ajic.2009.12.011. Epub 2010 Apr 3.
4
Community-onset bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis.产超广谱β-内酰胺酶大肠埃希菌引起的社区获得性菌血症:危险因素和预后。
Clin Infect Dis. 2010 Jan 1;50(1):40-8. doi: 10.1086/649537.
5
Molecular epidemiology of CTX-M-producing Escherichia coli isolates at a tertiary medical center in western Pennsylvania.宾夕法尼亚州西部地区一家三级医疗中心产 CTX-M 型大肠埃希菌的分子流行病学研究。
Antimicrob Agents Chemother. 2009 Nov;53(11):4733-9. doi: 10.1128/AAC.00533-09. Epub 2009 Aug 17.
6
A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing enterobacteriaceae in nonhospitalized patients.一项针对非住院患者感染产超广谱β-内酰胺酶肠杆菌科细菌危险因素的多国调查。
Clin Infect Dis. 2009 Sep 1;49(5):682-90. doi: 10.1086/604713.
7
Prevalence of CTX-M beta-lactamases in Philadelphia, Pennsylvania.宾夕法尼亚州费城CTX-Mβ-内酰胺酶的流行情况。
J Clin Microbiol. 2009 Sep;47(9):2970-4. doi: 10.1128/JCM.00319-09. Epub 2009 Jul 8.
8
Gastrointestinal tract colonization with fluoroquinolone-resistant Escherichia coli in hospitalized patients: changes over time in risk factors for resistance.住院患者胃肠道氟喹诺酮耐药性大肠杆菌定植:耐药危险因素随时间的变化
Infect Control Hosp Epidemiol. 2009 Jan;30(1):18-24. doi: 10.1086/592703.
9
Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.产超广谱β-内酰胺酶大肠埃希菌引起的社区感染
Arch Intern Med. 2008 Sep 22;168(17):1897-902. doi: 10.1001/archinte.168.17.1897.
10
The spread of CTX-M-type extended-spectrum beta-lactamases.CTX-M型超广谱β-内酰胺酶的传播
Clin Microbiol Infect. 2008 Jan;14 Suppl 1:33-41. doi: 10.1111/j.1469-0691.2007.01867.x.

产 CTX-M 型超广谱β-内酰胺酶阳性大肠埃希菌感染或定植的危险因素。

Risk factors for infection or colonization with CTX-M extended-spectrum-β-lactamase-positive Escherichia coli.

机构信息

Division of Infectious Diseases, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.

出版信息

Antimicrob Agents Chemother. 2012 Nov;56(11):5575-80. doi: 10.1128/AAC.01136-12. Epub 2012 Aug 13.

DOI:10.1128/AAC.01136-12
PMID:22890772
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3486585/
Abstract

There has been a significant increase in the prevalence of Enterobacteriaceae that produce CTX-M-type extended-spectrum β-lactamases. The objective of this study was to evaluate risk factors for infection or colonization with CTX-M-positive Escherichia coli. A case-control study was conducted within a university system from 1 January 2007 to 31 December 2008. All patients with clinical cultures with E. coli demonstrating resistance to extended-spectrum cephalosporins were included. Case patients were designated as those with cultures positive for CTX-M-positive E. coli, and control patients were designated as those with non-CTX-M-producing E. coli. Multivariable logistic regression analyses were performed to evaluate risk factors for CTX-M-positive isolates. A total of 83 (56.8%) of a total of 146 patients had cultures with CTX-M-positive E. coli. On multivariable analyses, there was a significant association between infection or colonization with CTX-M-type β-lactamase-positive E. coli and receipt of piperacillin-tazobactam in the 30 days prior to the culture date (odds ratio [OR], 7.36; 95% confidence interval [CI], 1.61 to 33.8; P = 0.01) and a urinary culture source (OR, 0.36; 95% CI, 0.17 to 0.77; P = 0.008). The rates of resistance to fluoroquinolones were significantly higher in isolates from case patients than in isolates from control patients (90.4 and 50.8%, respectively; P < 0.001). We found that nonurinary sources of clinical cultures and the recent use of piperacillin-tazobactam conferred an increased risk of colonization or infection with CTX-M-positive E. coli. Future studies will need to focus on outcomes associated with infections due to CTX-M-positive E. coli, as well as infection control strategies to limit the spread of these increasingly common organisms.

摘要

产 CTX-M 型超广谱β-内酰胺酶的肠杆菌科的流行率显著增加。本研究旨在评估感染或定植产 CTX-M 型大肠埃希菌的危险因素。这是一项在 2007 年 1 月 1 日至 2008 年 12 月 31 日期间在一个大学系统内进行的病例对照研究。所有具有对头孢菌素类药物表现出耐药性的大肠埃希菌临床培养物的患者均被纳入研究。病例组患者被指定为 CTX-M 阳性大肠埃希菌培养阳性的患者,对照组患者被指定为非产 CTX-M 大肠埃希菌的患者。采用多变量逻辑回归分析评估 CTX-M 阳性分离株的危险因素。在总共 146 例患者中,共有 83 例(56.8%)的培养物中发现了产 CTX-M 型β-内酰胺酶的大肠埃希菌。多变量分析显示,在培养日期前 30 天内接受哌拉西林-他唑巴坦治疗(比值比 [OR],7.36;95%置信区间 [CI],1.61 至 33.8;P = 0.01)和尿培养物来源(OR,0.36;95%CI,0.17 至 0.77;P = 0.008)与感染或定植产 CTX-M 型β-内酰胺酶的大肠埃希菌显著相关。与对照组患者相比,病例组患者的分离株对氟喹诺酮类药物的耐药率明显更高(分别为 90.4%和 50.8%;P < 0.001)。我们发现,非尿源临床培养物和近期使用哌拉西林-他唑巴坦会增加感染或定植产 CTX-M 型大肠埃希菌的风险。未来的研究将需要重点关注由产 CTX-M 型大肠埃希菌引起的感染相关结局,以及感染控制策略,以限制这些日益常见的病原体的传播。